Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1066 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 44, which is 18 points higher than the healthcare sector average of 26. It passed 14 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 47.73% over the past year, overperforming other healthcare stocks by 142 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 53.37% from Bioventus's current stock price of $9.78.

Bioventus stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Bioventus, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the #2 top healthcare stock out of 1066 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Jazz Pharmaceuticals (NASDAQ:JAZZ) is: Value: A, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: C.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a Due Diligence Score of 34, which is 8 points higher than the healthcare sector average of 26. It passed 11 out of 33 due diligence checks and has average fundamentals. Jazz Pharmaceuticals has seen its stock return 124.01% over the past year, overperforming other healthcare stocks by 219 percentage points.

Jazz Pharmaceuticals has an average 1 year price target of $259.25, an upside of 9.06% from Jazz Pharmaceuticals's current stock price of $237.72.

Jazz Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Jazz Pharmaceuticals, 66.67% have issued a Strong Buy rating, 25% have issued a Buy, 8.33% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Electromed (NYSEMKT:ELMD) is the #3 top healthcare stock out of 1066 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Electromed (NYSEMKT:ELMD) is: Value: C, Growth: C, Momentum: B, Sentiment: A, Safety: B, Financials: A, and AI: C.

Electromed (NYSEMKT:ELMD) has a Due Diligence Score of 44, which is 18 points higher than the healthcare sector average of 26. It passed 15 out of 33 due diligence checks and has strong fundamentals. Electromed has seen its stock return 92.04% over the past year, overperforming other healthcare stocks by 187 percentage points.

Electromed has an average 1 year price target of $38.00, a downside of -10.02% from Electromed's current stock price of $42.23.

Electromed stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Electromed, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 76 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Cryo Cell International (NYSEMKT:CCEL) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 2.62%.

Cryo Cell International's dividend payout ratio of -45.5% indicates that its dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 31.15%, which is 29 percentage points higher than the healthcare sector average of 2.62%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 16.62%, which is 14 percentage points higher than the healthcare sector average of 2.62%.

Siga Technologies's dividend payout ratio of 206.9% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.65% in the last day, and up 6.76% over the last week. Universe Pharmaceuticals was the among the top gainers in the healthcare sector, gaining 311.49% yesterday.

Universe Pharmaceuticals shares are trading higher after the company announced it will acquire Best Praise International for $10.75 million.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 43, which is 29 points higher than the healthcare sector average of 14. It passed 3 out of 7 valuation due diligence checks.

Embecta's stock has dropped -65.84% in the past year. It has overperformed other stocks in the healthcare sector by 29 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 72 points higher than the healthcare sector average of 14. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 499.72% in the past year. It has overperformed other stocks in the healthcare sector by 594 percentage points.

Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Collegium Pharmaceutical has a valuation score of 43, which is 29 points higher than the healthcare sector average of 14. It passed 3 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 21.68% in the past year. It has overperformed other stocks in the healthcare sector by 116 percentage points.

61.96% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 29.82% over the next year.

5.19% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.48% of healthcare stocks are rated B (Buy), 49.2% are rated C (Hold), 25.71% are rated D (Sell), and 7.42% are rated F (Strong Sell).